The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
In Vitro and in Vivo RNA Inhibition by CD9-HuR Functionalized Exosomes Encapsulated with miRNA or CRISPR/dCas9
Abstract
In vitro and in vivo delivery of RNAs of interest holds promise for gene therapy. Recently, exosomes are considered as a kind of rational vehicle for RNA delivery, especially miRNA and/or siRNA, while the loading efficiency is limited. In this study, we engineered the exosomes for RNA loading by constructing a fusion protein in which the exosomal membrane protein CD9 was fused with RNA binding protein, while the RNA of interest either natively harbors or is engineered to have the elements for the binding. By proof-of-principle experiments, we here fused CD9 with HuR, an RNA binding protein interacting with miR-155 with a relatively high affinity. In the exosome packaging cells, the fused CD9-HuR successfully enriched miR-155 into exosomes when miR-155 was excessively expressed. Moreover, miR-155 encapsulated in the exosomes in turn could be efficiently delivered into the recipient cells and recognized the endogenous targets. In addition, we also revealed that the CD9-HuR exosomes could enrich the functional miRNA inhibitor or CRISPR/dCas9 when the RNAs were engineered to have the AU rich elements. Taken together, we here have established a novel strategy for enhanced RNA cargo encapsulation into engineered exosomes, which in turn functions in the recipient cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In exosome-producing cells, the CD9-HuR fusion protein effectively enriched exosomes with miR-155 when miR-155 was overexpressed.”
From Exosome for mRNA delivery: Strategies and therapeutic applications (2024) · cites this paper as [105]
In the citing paper
“Moreover, miR-155 encapsulated in these exosomes can be efficiently delivered to recipient cells and target endogenous molecules (Fig. 2C) [105].”
From Exosome for mRNA delivery: Strategies and therapeutic applications (2024) · cites this paper as [105]
Citations
Cites
miRBase: annotating high confidence microRNAs using deep sequencing data
Kozomara, A., & Griffiths-Jones, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1181 · Cited by 5,073
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Extracellular vesicles: biology and emerging therapeutic opportunities
EL Andaloussi, S., Mäger, I., Breakefield, X. O., & Wood, M. J. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3978 · Cited by 3,571
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825
Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function
Zhang, J., Li, S., Li, L., Li, M., Guo, C., Yao, J., & Mi, S. (2015) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2015.02.001 · Cited by 1,901
Tian, Y., Li, S., Song, J., Ji, T., Zhu, M., Anderson, G. J., Wei, J., & Nie, G. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.083 · Cited by 1,841
Ambros, V. (2001) · Cell · doi:10.1016/s0092-8674(01)00616-x · Cited by 1,705
Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells
Ohno, S.-I., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K., Mizutani, T., Ohgi, T., Ochiya, T., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.180 · Cited by 1,666
LncRNA: A link between RNA and cancer
Yang, G., Lu, X., & Yuan, L. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.08.012 · Cited by 992
Self-citationLu, L., Thai, T., Calado, D. P., Chaudhry, A., Kubo, M., Tanaka, K., Loeb, G. B., Lee, H., Yoshimura, A., Rajewsky, K., et al. (2009) · Immunity · doi:10.1016/j.immuni.2008.11.010 · Cited by 797
Flagged first, then by citations
Cited by
Sorted by citations
Zhang, Y., Bi, J., Huang, J., Tang, Y., Du, S., & Li, P. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s264498 · Cited by 1,323
CRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 824
Meng, W., He, C., Hao, Y., Wang, L., Li, L., & Zhu, G. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1748758 · Cited by 592
Salunkhe, S. A., Dheeraj, Basak, M., Chitkara, D., & Mittal, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.042 · Cited by 513
Engineered exosomes from different sources for cancer-targeted therapy
Zhang, M. H., Hu, S., Liu, L., Dang, P., Liu, Y., Sun, Z., Qiao, B., & Wang, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01382-y · Cited by 493
Metadata
- Authors
- Li, Z., Zhou, X., Wei, M., Gao, X., Zhao, L., Shi, R., Sun, W., Duan, Y., Yang, G., & Yuan, L.
- Affiliations
- Tang Du Hospital (CN)
- Air Force Medical University (CN)
- Corresponding author
- Yang, Guodong
- Yuan, Lijun
- Venue
- Nano Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-12-05
- Volume
- 19
- Issue
- 1
- Pages
- 19-28
- ISSN
- 1530-6984 (ISSN-L)
- 1530-6992
- OpenAlex
- W2903480993
- Cited by
- 318
- References
- 34
- Citations by year
- 2026: 27 · 2025: 33 · 2024: 54 · 2023: 56 · 2022: 55 · 2021: 43 · 2020: 36 · 2019: 13
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nano Letters (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81671690, 81871357, 31771507)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- engineered exosomes, RNA delivery, microRNA delivery, CRISPR/dCas9, miR-155, AU-rich elements, RNA-binding proteins, gene therapy vectors
- MeSH terms
- ELAV-Like Protein 1, Animals, Cell Line, Humans, RNA-Binding Proteins, Gene Transfer Techniques, RNA, Small Interfering, MicroRNAs, Mice, Exosomes, Tetraspanin 29, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
